medigraphic.com
ISSN 1561-2988 (Print)

2011, Number 4

<< Back Next >>

Rev Cubana Farm 2011; 45 (4)

Role of statistics in the clinical trials

Robaina GM, Fors LMM

Language: Spanish
References: 41
Page: 575-585
PDF size: 60.78 Kb.


ABSTRACT

The complexity and high costs associated to the development of drugs have brought about the search for more efficient strategies combining time saving and research quality. The statistical methodology plays a fundamental role in this process. The present paper made a literature review of the role of statistics in therapeutic research. The objectives were to describe how statistics participate in the clinical trials and to present some advances attained as well as the challenges met by the biostatician in the present context of development of these studies. The statistical process was described in the clinical trial from the practical viewpoint, including regulatory demands and documentary availability. Some specific methodological topics as well as application-developed statistical techniques were presented. It was concluded that the statistical methodology in clinical trials has experienced growing development in the last few years. The research suggested the use of flexible designs that would speed up the most sensitive studies and methods of analysis. The regulatory bodies set guidelines that give instructions for the harmonized presentation of clinical trials under various circumstances. The application of more sensitive statistical techniques and the use of technologies supporting these advances is a subject that is increasingly dealt with by the scientific literature on clinical trials.


REFERENCES

  1. Backgrounder: How New Drugs Move through the Development and Approval Process. Boston. November 1, 2001. Available from: http://csdd.tufts.edu/files/uploads /how_new_drugs_move.pdf

  2. Gilbert J, Henske P, Singh A. Rebuilding Big Pharma's Business Model, in vivo, the Business & Medicine Report, Windhover Information, 2003; 21(10). Available from: http://www.bain.com/Images/rebuilding_big_pharma.pdf

  3. Challenge and opportunity on the Critical Path to New Medical Products. US Department of Health and Human Services Food and Drug Adminsitration. March 2004. [cited 2010 Aug 12]. Available from: http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm077262.htm

  4. Critical Path Opportunities Report. US Department of Health and Human Services Food and Drug Adminsitration, March, 2006. [cited 2010 Aug 12]. Available from: http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/UCM077254.pdf

  5. Sitio web de la Agencia Regulatoria en Cuba: Centro para el Control Estatal de la Calidad de los Medicamentos. CECMED. [citado 13 Sept 2010]. Disponible en: http://www.cecmed.sld.cu/

  6. Buenas Prácticas Clínicas en Cuba. Centro para el Control Estatal de la Calidad de los Medicamentos. CECMED. MINSAP. La Habana. 2000. [citado 13 Sept 2010]. Disponible en: http://www.cecmed.sld.cu/Docs/RegFarm/DRA/EvalDC/Reg/Dir_BPC.pdf

  7. International Conference on Harmonisation. E6 (R1): Good Clinical Practice: Consolidated Guideline. Tripartite harmonised ICH guideline 1996. [cited 2010 Aug 12]. Available from: http://www.ich.org/cache/compo/276-254-1.html

  8. International Conference on Harmonisation. E6 (R1): Good Clinical Practice: Consolidated Guideline.Tripartite harmonised ICH guideline 1996. [cited 2010 Aug 12]. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6_R1/Step4 /E6_R1__Guideline.pdf

  9. International Conference on Harmonisation. E3: Structure and Content of Clinical Study Reports. Tripartite harmonised ICH guideline, 1995. [cited 2010 Feb 10]. Available from: http://www.crc.gov.my/documents/ICH%20E3.pdf

  10. International Conference on Harmonisation. E9: Statistical Principles for Clinical Trials. Tripartite harmonised ICH guideline, 1998. [cited 2010 Aug 12]. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/Step4 /E9_Guideline.pdf

  11. Bailar III JC, Mosteller F. Guidelines for Statistical Reporting in Articles for Medical Journals. Amplifications and Explanations. Annals of Internal Medicine, 15 February 1988. 108:266-273. [cited 2010 Feb 10]. Available from: http://www.people.vcu.edu/~albest/Guidance/guidelines_for_statistical_reporting.htm

  12. Schulz KF, Altman DG, Moher D for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Trials 2010, 11:32. [cited 13 Sep 2010. Available from: http://www.trialsjournal.com/content/11/1/32

  13. Sitio web del grupo CONSORT. citado 13 Sep 2010]. Disponible en: http://www.consort-statement.org

  14. Robaina M, Uranga R. Software estadístico en los ensayos clínicos. Rev Cubana Inform Med. 2007; 3. [citado 13 Ago 2010]. Disponible en: http://www.cecam.sld.cu/pages/rcim/revista_14/articulos_htm/ensayosclinicos.htm

  15. Piantadosi S. Clinical Trials A Methodological Perspective. 2nd ed. New York: John Wiley & Sons; 2005.

  16. Senn S. Statistical Issues in Drug Development. 2nd ed. New York: John Wiley & Sons; 2007.

  17. Anello Ch. Emerging and recurrent issues in drug development. Statistics Med. 1999;18:2301-9.

  18. Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet. 2000;355:1064-9.

  19. Westfall P, Bretz F. Multiplicity in Clinical Trials. In: Chow SC (ed.). Encyclopedia of Biopharmaceutical Statistics. 2nd ed. New York: Marcel Dekker Inc; 2003. p. 666-73.

  20. Molenberghs G, Kenward M. Missing Data in Clinical Studies. New York: Springer-Verlag; 2007.

  21. Chow Shein-Chung, Chang M. Adaptive Design Methods in Clinical Trials. New York: Chapman and Hall; 2007.

  22. Posch M, Bauer P, Brannath W. Flexible design. Wiley Encyclopedia of Clinical Trials. New York: John Wiley & Sons, Inc; 2007.

  23. Evans CHJr, Ilstad ST, eds. Small Clinical Trials: Issues and Challenges. Washington, DC: National Academy Press; 2001.

  24. Food and Drug Administration (FDA). Available from: http://www.fda.gov

  25. Agencia Europea Regulatoria de Medicamentos (EMEA). Disponible en: http://www.ema.europa.eu/ema/index.jsp?curl=pages/home/Home_Page.jsp&murl=&mid=

  26. FDA. Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials. Available from: 2010. http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/General/ucm217041.htm

  27. FDA. Guidance for non inferiority clinical trials. 2010. Available from: http://www.fda.gov/downloads/Drugs/NewsEvents/UCM209083.pdf

  28. FDA. Adaptive Design Clinical Trials for Drugs and Biologics. 2010. Available from: http://www.healthindustrywashingtonwatch.com/2010/03/articles/other-fdadevelopments/fda-draft-guidance-on-adaptive-design-clinical-trials-for-drugs-andbiologics/

  29. EMEA. EMA/CPMP/EWP/1776/99.Rev.1. Guideline on Missing Data in Confirmatory Clinical Trials. 2011. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/09/WC500096793.pdf

  30. EMEA. Guidelines on Clinical Trials in Small Populations. 2006. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003615.pdf

  31. EMEA. CHMP/EWP/2459/02. Reflection paper on methodological issues in confirmatory clinical trials planned with an adaptive design. 2007. Available from: http://home.att.ne.jp/red/akihiro/emea/245902enadopted.pdf

  32. Guías generales para la evaluación de eficacia y seguridad de productos en humanos. Agencia Europea de Medicamentos. EMEA. Disponible en: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000366.jsp&murl=menus/regulations/regulations.jsp&mid=WC0b01ac0580032ec4

  33. Simon R. New challenges for 21st century clinical trials. Clin Trials. 2007;4:167-9.

  34. Geli i Fabra M. La medicina predictiva y personalizada. [citado 12 Ago 2010]. Disponible en: http://www.institutoroche.es/doc.php?op=medicina&id=11

  35. Simon R. Clinical trials for predictive medicine: new challenges and paradigms. Clin Trials. 2010;7:516-24.

  36. DeMets DL, Stormo G, Boehnke M, Louis TA, Taylor J, Dixon D. Training of the next generation of biostatisticians. Stat Med. 2006:25;3415-29.

  37. Greenhouse SW. The growth and future of biostatistics: (A view from the 1980s). Stat Med. 2003;22:3323-35.

  38. Zelen M. Biostatisticians, Biostatistical Science and the Future. Stat Med. 2006; 25:3409-14.

  39. Gehan EA. Biostatistics in the new millennium: a consulting statistician's perspective. Stat Met Med Res. 2000;9:3-16.

  40. Berry Donald A. Bayesian clinical trials. Nat Rev Drug Discovery. 2006;5:27-36.

  41. Davidian M, Tsiatis AA, Leon S. Semiparametric Estimation of Treatment Effect in a Pretest-Posttest Study with Missing Data. Stat Sci. 2005 Aug;20(3):261-301.




2020     |     www.medigraphic.com